Myanmar vs Tajikistan: Access to anti-retroviral drugs, male
Myanmar
73.0%
in 2024
Tajikistan
72.0%
in 2024
Myanmar rank
62nd
Tajikistan rank
65th
Access to anti-retroviral drugs, male over time
- Myanmar
- Tajikistan
How they compare
Myanmar currently reports 73.0% against 72.0% in Tajikistan, a difference of 1.0%.
The two have swapped places 1 time across 25 shared years of data; in 2000 it was Tajikistan ahead.
Myanmar ranks 62nd and Tajikistan ranks 65th of 141 countries.
Myanmar has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Myanmar | Tajikistan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 2.2% | 0.7% | 1.5% | Myanmar |
| 2010s | 34.8% | 19.3% | 15.5% | Myanmar |
| 2020s | 71.2% | 59.2% | 12.0% | Myanmar |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Myanmar or Tajikistan?
- Myanmar, at 73.0% against 72.0% in Tajikistan as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Myanmar and Tajikistan?
- 1.0%, with Myanmar ahead.
- How many years of comparable data are there for Myanmar and Tajikistan?
- 25 years are reported by both, from 2000 to 2024.
- How do Myanmar and Tajikistan rank globally for access to anti-retroviral drugs, male?
- Myanmar ranks 62nd and Tajikistan ranks 65th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.